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Abstract. Primary spinal glioblastoma (GBM) is a rare 
disease, with an aggressive course and a poor prognosis. We 
report a case of a 19-year-old male with a 4-week history of 
progressive weakness in both lower limbs, which progressed 
to paraparesis with a left predominance and difficulty in 
initiating urination over a week. Spine magnetic resonance 
imaging (MRI) showed an intramedullary expansile mass 
localised between T6 and T11. We performed a laminotomy 
and laminoplasty between T6 and T11 and the tumour was 
partially removed. Histopathological study was compatible 
with GBM. The patient was administered focal spine radio-
therapy with chemotherapy with temozolamide. Serial MRI 
performed after the initial surgery demonstrated enlargement 
of the enhancing mass from T3 to T12 and subarachnoid 
metastatic deposits in C2 and C4, the pituitary stalk, inter-
peduncular cistern, left superior cerebellar peduncle and 
hydrocephalus. We review the literature with regard to the 
disease and treatment options, and report the unique features 
of this case. Primary spinal GBM is an extremely rare entity 
with a poor prognosis and a short survival time. An aggressive 
management of the different complications as they arise and 
improvement of current modes of treatment and new treatment 
options are required to improve survival and ensure better 
quality of life.
Introduction
Astrocytoma is the most common primary tumour of the 
central nervous system (1). Spinal neoplasms in the adult 
population are mostly extradural (55%) and intradural extra-
medullary tumours (40%), whereas intramedullary tumours 
account for 5% of all spinal cord tumours, excluding metastatic 
lesions (2). Of these, ~30% are tumours of low malignancy, 
including slow-growing astrocytomas and ependymomas. 
Spinal cord astrocytomas are rare, representing ~1% of all 
primary central nervous system tumours and 6 to 8% of all 
spinal cord tumours (3). Few spinal cord astrocytomas are 
anaplastic in nature; most are slow-growing lesions. The 
ratio of low-grade to high-grade astrocytomas in the spinal 
cord is ~3 to 1 (4,5). Glioblastomas (GBMs) represent ~7.5% 
of all intramedullary gliomas and 1 to 3% of all spinal cord 
tumours (4,6). Moreover, GBM has a predilection of devel-
opment at the cervical or cervicothoracic region in >60% 
of cases (1,7-9). Clinical presentation is associated with the 
region of spinal cord involved, irrespective of tumour type. 
Unlike their intracranial counterpart, intramedullary GBMs 
have received scant attention in the literature, with <200 cases 
reported. Even with aggressive management, these tumours 
are generally associated with a dismal outcome.
Case report
A 19-year-old male was transferred to our institution in 
May 2010 with a 4-week history of progressive weakness 
in both lower limbs, which progressed to paraparesis with a 
left predominance and difficulty in initiating urination over 
a week. Examination revealed spastic paraparesis (right/left: 
grade 4+ and 3+, respectively) and hypoesthesia below the T10 
sensory dermatome.
The study was approved by the Ethics Committee of 
Hospital de Braga, Braga, Portugal. Informed consent was 
obtained from the patient's family.
The patient underwent brain and spine magnetic resonance 
imaging (MRI). The brain and cervical spine were negative 
for masses and signal intensity alterations, whereas from T1 
to L1 there was a marked spinal cord signal intensity and 
morphology alteration, with notable spinal cord expansion 
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between T6 and T11 and contrast enhancement between T6 
and T9 (Fig. 1).
We performed a laminotomy and laminoplasty between 
T6 and T11, and partial tumour removal under motor-evoked 
potential monitoring. We were unable to distinguish the 
tumour margin from the spinal cord and decided to partially 
remove the mass.
Histopathological study confirmed the diagnosis of GBM 
(Fig. 2), with histological findings of pleomorphism, atypical 
cells with high cellularity, vascular proliferation and necrosis. 
As demonstrated by immunohistochemistry, glial fibrillary 
acidic protein (GFAP) and S100 Protein were consistently 
expressed by tumour cells. The neoplasm also showed a high 
MIB1/Ki-67 labelling index.
Post-operatively the patient had transient neurological 
deterioration with worsening of paraparesis, but with 
intensive rehabilitation his condition returned to baseline. 
Thoracoabdominal CT scan for extra-neuronal metastases was 
negative. The patient was administered spinal radiotherapy 
between T1 and L1 (45 Gy in 28 fractions) with chemotherapy 
with temozolamide (completed 6 cycles). 
Serial MRI at 3, 6 and 17 months was performed (Fig. 3). 
Six months after surgery the patient deteriorated, becoming 
completely paraplegic and losing bladder function. Cranial 
and spine MRI revealed enlargement of the residual tumour 
from T3 to T12 with cranial extension of oedema to the obex, 
and subarachnoid metastatic deposits in C2, C4 and in the 
pituitary stalk, with hydrocephalus. We proposed cranio-
Figure 1. Spine MRI. (A) T1, (B) T1 with contrast and (C) T2-weighted dorsal spine sagittal view MRI at presentation, demonstrating the presence of the 
tumour between T1 and L1. (D) T1, (E) T1 with contrast and (F) T2-weighted dorsal spine sagittal view MRI 3 months after surgery. (G) T1, (H) T1 with 
contrast and (I) T2-weighted dorsal spine sagittal view MRI 17 months after surgery, demonstrating enlargement of the enhancing mass from T3 to T12 with 
subarachnoid metastatic deposit in C2 and C4. MRI, magnetic resonance imaging. 
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spinal irradiation, but as the patient was stable and without 
signs or symptoms of increased intracranial pressure (ICP) 
the patient and his family decided to withhold this treatment 
and wait.
Figure 2. Histological findings of glioblastoma. (A) High MIB-1 /Ki-67 labelling index. (B) Marked immunoreactivity for GFAP. (C and D) Pleomorphic glial 
tumour cells with marked nuclear atypia. (E) Vascular proliferation was observed throughout the lesion. (F) Presence of extensive areas of necrosis. (A-E) 
Magnification, x400. (F) Magnification, x100. (C-F) Hematoxylin/eosin staining. GFAP, glial fibrillary acidic protein.
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Figure 3. MRI of the brain. (A) Axial section, contrast-enhanced T1-weighted MRI of the brain, at presentation, demonstrating no lesions. (B and D) Axial 
and sagittal section, respectively, contrast-enhanced T1-weighted MRI of the brain, at 6 months after initial presentation, showing a metastatic deposit in the 
pituitary stalk. (C) Axial and (E) sagittal section contrast-enhanced T1-weighted MRI of the brain, at 17 months after initial presentation, demonstrating new 
metastatic deposits in the interpeduncular cistern and in the left superior cerebellar peduncle. MRI, magnetic resonance imaging.
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Neuroaxis MRI performed 17 months after surgery revealed 
an enlargement of the enhancement mass from T3 to T12 with 
less perilesional oedema and a new metastatic deposit in the 
interpeduncular cistern and left superior cerebellar peduncle.
On the follow-up 20 months after surgery, the patient 
presented with a left third cranial nerve paralysis and bilateral 
mydriasis without signs of increased ICP or mental status 
change. CT scan showed larger ventricles and enlargement 
of the pituitary stalk and left superior cerebellar peduncle 
metastatic deposits. Given the disease progression and the 
Karnofsky score (40%), we did not consider further treatment 
and the patient succumbed to the disease 1 month later.
Discussion
Intramedullary GBM is a rare disease entity. It develops 
primarily from the spinal cord or as a secondary metastasis 
from the brain, which covers up to 25% of the total occur-
rences. Intramedullary GBM has a predilection to develop 
from the cervical region in primary cases, and has a tendency 
to develop at a young age (<30 years old). Despite the best 
treatment (surgery and adjuvant therapy), the estimated 
survival barely exceeds 6 to 16 months (1,8-11).
Certain patients with malignant spinal cord astrocytomas 
develop hydrocephalus (1,7), which is thought to be due to 
increased protein concentration in the cerebrospinal fluid 
(CSF), occlusion of the CSF channel in the subarachnoid space 
at the skull base and brain surface, arachnoiditis and bleeding 
of spinal cord tumours (6,7).
Seeding of an intracranial GBM along the spine occurs 
in 25% of cases, but the reverse process is extremely 
uncommon (1,3). Patients with malignant spinal cord astro-
cytomas may develop disseminated disease, mostly via the 
leptomeningeal route (1,6); however, no definite evidence has 
been elucidated. Sites of intracranial metastases include the 
subarachnoid space, ventricles, cerebellum, hypothalamus, 
brain stem, thalamus and septum pellucidum. Surgical manip-
ulation of GBM has not been shown to increase the tumour 
seeding into the CSF (3). Continuous spread to contiguous 
regions is rare, with the most common sites metastases being 
extra-neuronal, including the lungs, lymph nodes, bone, liver 
and pleura (12). In our case, metastases were observed in the 
subarachnoid space in C2 and C4, pituitary stalk, interpedun-
cular cistern and left superior cerebellar peduncle.
All current therapeutic measures have produced disap-
pointing results and few data concerning their real value are 
available, with survival times between 6 and 16 months with 
a mean survival period of 12 months after diagnosis (1,4,7-10) 
Radical surgery is suggested for confirmation of the diagnosis 
and for cytoreduction of the tumour as an adjunct to radio-
therapy and chemotherapy. 
Most authors suggest focal spine radiotherapy and chemo-
therapy with temozolamide, while others recommend a more 
aggressive approach with whole-brain irradiation in addition to 
focal spine irradiation, even if there is no evidence of intracra-
nial dissemination. Others suggest intrathecal administration 
of interferon-β via an Ommaya reservoir in conjunction with 
cranio-spinal irradiation (3,7).
MRI is considered the gold standard imaging modality 
to diagnose intramedullary tumours (13,14), and gadolinium-
enhanced MRI of the entire neuroaxis is advocated to rule out 
metastasis, evaluate treatment efficacy and detect relapse (15).
To the best of our knowledge, only 16 cases of spinal 
GBM involving the conus medullaris have been previously 
reported (1,4,13-19,20-24), making this case the first with 
spinal and intracranial metastasis with hydrocephalus and the 
third most longest survival (21 months).
In conclusion, primary spinal GBM is an extremely rare 
entity. Despite aggressive treatment with radical surgery, 
radiotherapy and chemotherapy, this disease progresses rapidly 
with a poor prognosis and a short survival time. We advocate 
an aggressive management of the different complications as 
they arise (progression, metastasis, hydrocephalus) to extend 
the patient's survival as long as possible with the best quality 
of life. Improvement of current modes of treatment and new 
treatment options (chemotherapy protocols, gene therapy) are 
required to improve survival and ensure better quality of life.
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